⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNTI News
Senti Biosciences, Inc. Common Stock
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
globenewswire.com
SNTI
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
globenewswire.com
SNTI
Form 8-K
sec.gov
SNTI
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
SNTI
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
SNTI
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
globenewswire.com
SNTI
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
globenewswire.com
SNTI
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
globenewswire.com
SNTI
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
globenewswire.com
SNTI
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
globenewswire.com
SNTI